The Gastric Organoids
- Challenges in research on human stomach and gastric cancer
- Opportunities on organoid technology in scientific research
- Application of gastric organoids in research
- Example on limitation of current organoid research
- Some future trends on organoid-related cancer research
- Selected compositions for gastric epithelial organoid culture recipe by Lab-A-Porter
Challenges in research on human stomach and gastric cancer
- These models establish unnatural geometric and mechanical constraints by adhering cells to an artificial substrate (either plastic or glass). 
- Such as culture affects cell polarity and therefore, potentially, tumour phenotypes. 
- However, these models have all shown limitations connected to genetic background irrelevance, animal resistance and the inability to allow examination of the mechanisms that characterize the aggressive metastasis tumours 
Opportunities on organoid technology in scientific research
- Gastric cancer ranking as the fifth most common malignancy, the third leading cause of cancer-related deaths. 
- Gastric cancer is a heterogenous disease displaying many different histological and molecular subtypes [1,3]
- The prognosis of gastric cancer is poor and most advanced forms of the disease remain incurable. 
- Although treatment effectiveness has improved during the past decade, gastric cancer survival rates remain poor. 
- This suggests an urgent need to advance innovative therapies available to gastric cancer patients. 
- Nanki and colleagues have generated 37 PDO lines. 
- They obtained patient-derived organoids of all gastric tumour subtypes except for the Epstein-Barr virus-associated one. 
- Established patient-derived organoids recapitulated the same histopathological features as the original tumour. 
- Yan and colleagues have established 46 PDOs. 
- They classified them into 4 gastric subtypes with comparable mutational spectra. 
- They observed sub-clonal tumour evolution by comparing multiple biopsies obtained from the primary tumour or even metastasis of the same patient. 
- Nanki and colleagues have generated 37 PDO lines. 
Application of gastric organoids in research
- Use organoids as a preclinical model
- Use human and mouse organoids for disease modelling
- Use patient-derived organoids to personalize medicine for gastric cancer patients
- They can be rapidly established and expanded in a relatively short time for in vitro drug screening experiments, for therapy prediction and guidance. 
Example on limitation of current organoid research
- Organoids only contain epithelial layers without tissue microenvironments, such as the immune system and nervous system. 
- Fully maturation to adult organs or tissues is a bottleneck needed to be addressed. 
- Dependence on the extracellular matrix or basement membrane extract of current organoids. 
- The culture medium needs to be further refined for the long-term expansion of some organoids. 
- Growth factors or molecular inhibitors in culture medium might have some effects on drug responses of organoids. 
Some future trends on organoid-related cancer research
- Current data suggest a good predictive value of patient-derived organoids in drug and radiation assays, even if the overall mutational landscape is unknown.
- The evolution of translational research, through its applications with patient-derived tumour organoid models, makes it emerge as a crucial strategy in personalized medicine programs. 
- New clinical trials are required to further validate the benefits of gastric cancer patient-derived tumour organoids in personalized medicine.
- To assess the correlation between the in vivo primary tumour response and the ex vivo drug-mediated cytotoxicity. 
Selected compositions for gastric epithelial organoid culture recipe by Lab-A-Porter
Xeno-free (animal origin-free) hydrogel system for organoid culture
- Busslinger, Georg A et al. “The potential and challenges of patient-derived organoids in guiding the multimodality treatment of upper gastrointestinal malignancies.” Open biologyvol. 10,4 (2020): 190274. doi:10.1098/rsob.190274
- Seidlitz, Therese et al. “Gastric organoids-an in vitro model system for the study of gastric development and road to personalized medicine.” Cell death and differentiation vol. 28,1 (2021): 68-83. doi:10.1038/s41418-020-00662-2
- Alzeeb, George et al. “Three-Dimensional Culture Systems in Gastric Cancer Research.” Cancersvol. 12,10 2800. 29 Sep. 2020, doi:10.3390/cancers12102800
- Lo, Yuan-Hung et al. “A CRISPR/Cas9-Engineered ARID1A-Deficient Human Gastric Cancer Organoid Model Reveals Essential and Nonessential Modes of Oncogenic Transformation.” Cancer discovery vol. 11,6 (2021): 1562-1581. doi:10.1158/2159-8290.CD-20-1109
- Xu, Hanxiao et al. “Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine.” Experimental hematology & oncology vol. 7 30. 5 Dec. 2018, doi:10.1186/s40164-018-0122-9
Our xeno-free hydrogel system (VitroGel®) can closely mimic the natural extracellular matrix and open the door to clinical applications for 3D organoid models. Cells from different sources such as patient-derived cells can be cultured with our system with full lab automation potential for personalized 3D cell models, including highly complicated organoid models and co-culture systems.
BioGems has positioned itself to become a highly competitive source for a wide range of Small Molecules, Flow Cytometry Antibodies, Media Supplements, Antibodies, and a wide range of ECM’s. To keep up with the rapidly advancing research fronts, BioGems continuously adds new products to its comprehensive catalogue.
Our products are subjected to thorough and rigorous quality and performance testing to ensure that every product meets the highest standards. Providing our customers with the highest quality products at affordable prices is our goal.
Cytokines & growth factors
PeproTech creates the building blocks of your life science research by manufacturing high-quality products that advance scientific discovery and human health. Since 1988, we have grown into a global enterprise with state-of-the-art manufacturing facilities in the US, and offices around the world.
With over 2,000 products, PeproTech has developed and refined innovative protocols to ensure quality, reliability, and consistency.
Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health.
The company leverages machine learning, automation, and gene editing to build platforms for science at scale. With its foundations in engineering disciplines, the company’s platform technologies vertically integrate proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance basic research, target validation, and clinical trials.